Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19

Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19

Despite effective vaccines and treatments for COVID-19, clinical burden persists. An unmet need exists for additional effective agents with safety profiles allowing use across a broad population. Ibuzatrelvir is an orally bioavailable SARS-CoV-2 Mpro inhibitor that has demonstrated in vitro antivira...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2024-11
Hauptverfasser: Mortezavi, Mahta, Sloan, Abigail, Singh, Ravi Shankar P, Chen, Luke F, Kim, Jin Hyang, Shojaee, Negin, Toussi, Sima S, Prybylski, John, Baniecki, Mary Lynn, Bergman, Arthur, Banerjee, Anindita, Allerton, Charlotte, Alami, Negar Niki
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Despite effective vaccines and treatments for COVID-19, clinical burden persists. An unmet need exists for additional effective agents with safety profiles allowing use across a broad population. Ibuzatrelvir is an orally bioavailable SARS-CoV-2 Mpro inhibitor that has demonstrated in vitro antiviral activity and low potential for safety concerns, including drug-drug interactions. This phase 2b, double-blind, randomized clinical trial enrolled US adults aged 18‒
ISSN:1058-4838
1537-6591
1537-6591
DOI:10.1093/cid/ciae529